<DOC>
	<DOC>NCT02132988</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based chemotherapy as initial treatment for primary disease or as salvage treatment for first relapse.</brief_summary>
	<brief_title>Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Female subjects ≥ 21 years of age with histologically confirmed ≥ stage II epithelial ovarian, fallopian tube, and primary peritoneal cancer at diagnosis Who have not progressed after initial treatment with cytoreductive surgery and at least 4 cycles of platinumbased chemotherapy. OR Female subjects ≥ 21 years of age with first relapsed epithelial ovarian, fallopian tube, and primary peritoneal cancer (regardless of stage at diagnosis) Who have not progressed after received at least 4 additional cycles of platinumbased chemotherapy with or without having undergone secondary cytoreductive surgery . Subjects with evidence of disease progression according to the GCIG CA125 criteria or RECIST 1.1 criteria. Subjects who are currently receiving any other concomitant anticancer therapy. Subjects with evidence of extraabdominal metastasis.</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>